Caraco's Detroit plant rehab timeline extended

Caraco says it's unlikely to resume manufacturing at its Detroit facility before April, as it had estimated earlier. Following a review with its GMP consultants on the remediation steps completed since it entered into a consent decree with the FDA in September 2009, and those still pending, the generics maker has revised its restart estimate. Remediation continues, the company says, but it can't predict when manufacturing and distribution operations will resume. Caraco release  

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)